Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Sabra Health Care REIT, Inc. (SBRA)
|
Add to portfolio |
|
|
Price: |
$13.83
| | Metrics |
OS: |
231.2
|
M
| |
|
|
Market cap: |
$3.2
|
B
| |
|
|
Net debt:
|
$1.86
|
B
| |
13.3
|
x Debt/EBITDA
|
EV:
|
$5.05
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
$140
|
M
| |
36.2
|
x EV/EBITDA
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
Revenues | 569.5 | 598.6 | 661.7 | 623.4 | 408.3 | 260.5 | 238.9 | 183.5 |
Revenue growth | -4.8% | -9.5% | 6.1% | 52.7% | 56.7% | 9.1% | 30.2% | 36.2% |
Cost of goods sold | 243.4 | 231.7 | 234.2 | 231.2 | 17.9 | 5.7 | 2.6 | 1.9 |
Gross profit | 326.2 | 366.9 | 427.5 | 392.2 | 390.4 | 254.8 | 236.3 | 181.6 |
Gross margin | 57.3% | 61.3% | 64.6% | 62.9% | 95.6% | 97.8% | 98.9% | 98.9% |
General and administrative | 34.7 | 32.8 | 30.9 | 37.1 | 32.4 | 17.7 | 16.1 | 23.8 |
EBITA | -12.4 | 64.9 | 87.7 | 9.2 | 138.0 | 97.7 | 144.3 | 71.4 |
EBITA margin | -2.2% | 10.8% | 13.3% | 1.5% | 33.8% | 37.5% | 60.4% | 38.9% |
Amortization of intangibles | 8.7 | 10.6 | 17.7 | | | | | |
EBIT | -21.1 | 54.3 | 70.0 | 9.2 | 138.0 | 97.7 | 144.3 | 71.4 |
EBIT margin | -3.7% | 9.1% | 10.6% | 1.5% | 33.8% | 37.5% | 60.4% | 38.9% |
Pre-tax income | 80.7 | 155.7 | 79.2 | 287.6 | 159.0 | 71.3 | 80.1 | 46.9 |
Income taxes | -1.8 | -0.7 | -3.4 | -3.0 | 0.7 | 1.0 | 0.7 | 0.0 |
Tax rate | | | | | 0.4% | 1.5% | 0.9% | 0.0% |
Net income | -113.3 | 138.4 | 69.0 | 269.3 | 148.1 | 60.0 | 69.2 | 36.7 |
Net margin | -19.9% | 23.1% | 10.4% | 43.2% | 36.3% | 23.0% | 29.0% | 20.0% |
|
Diluted EPS | ($0.52) | $0.67 | $0.37 | $1.51 | $1.40 | $0.92 | $1.11 | $0.78 |
Shares outstanding (diluted) | 219.1 | 207.3 | 188.1 | 178.7 | 105.8 | 65.5 | 62.5 | 46.9 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|